Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
Influence of Sarcopenia in Hepatocellular Carcinoma Patients
- Conditions
- Sarcopenia
- Interventions
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Sohag University
- Target Recruit Count
- 600
- Registration Number
- NCT06177496
Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Damanhour University
- Target Recruit Count
- 100
- Registration Number
- NCT06030895
- Locations
- 🇪🇬
Mansoura University Hospital, Mansoura, El-Dakahelia, Egypt
Evaluating the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib (XS005) in Healthy Male Subjects
- Conditions
- PharmacokineticsBioavailability
- Interventions
- Drug: XS005 Sorafenib Tablet A - Period 2Drug: XS005 Sorafenib Capsule A - Period 1Drug: XS005 Sorafenib Capsule A - Period 2Drug: XS005 Sorafenib Capsule A - Period 3Drug: XS005 Sorafenib Tablet A - Period 1Drug: XS005 Sorafenib Tablet A - Period 3
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Xspray Pharma AB
- Target Recruit Count
- 15
- Registration Number
- NCT05967377
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma
- Conditions
- RadiomicsHepatocellular Carcinoma (HCC)Transcatheter Arterial Chemoembolization (TACE)Multi-kinase Inhibitors (MKI)Microvascular Invasion (MVI)
- Interventions
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 200
- Registration Number
- NCT05889949
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT05822752
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers - Denver Midtwon /ID# 254163, Denver, Colorado, United States
🇮🇹IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 253247, Bologna, Emilia-Romagna, Italy
🇺🇸Arizona Oncology Associates, PC - NAHOA Prescott Valley /ID# 254313, Prescott Valley, Arizona, United States
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma Non-resectable
- Interventions
- Procedure: TACEDrug: Anti-PD-1 monoclonal antibody
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT05717738
- Locations
- 🇨🇳
Optical Valley branch of Tongji hospital, Wuhan, Hubei, China
🇨🇳The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China
🇨🇳Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Combined HAIC, TKI/anti-VEGF and ICIs As Conversion Therapy for Unresectable Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma Non-resectable
- Interventions
- Procedure: HAICDrug: Anti-PD-1 monoclonal antibody
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Ze-yang Ding, MD
- Target Recruit Count
- 300
- Registration Number
- NCT05713994
- Locations
- 🇨🇳
The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China
🇨🇳TongjiHospital, Wuhan, Hubei, China
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 12
- Registration Number
- NCT05669339
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
The Gut Microbiome in FLT3- AL Undergoing Allo-HSCT With Or Without Sorafenib Maintenance
- Conditions
- Acute LeukemiaAllogeneic Hematopoietic Stem Cell Transplantation
- Interventions
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 60
- Registration Number
- NCT05601895
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD MutationAllogeneic Hematopoietic Stem Cell Transplantation
- Interventions
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 60
- Registration Number
- NCT05596981
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.